Broadfin Capital Has Upped Nuvasive (NUVA) Position By $1.77 Million; Steris (STE) Sentiment Is 0.5

February 18, 2018 - By Marie Mckinney

STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support services and products for healthcare, pharmaceutical, scientific, research, industrial, and governmental clients worldwide. The company has market cap of $7.65 billion. The companyÂ’s Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories. It has a 31.74 P/E ratio. It also provides OR integration, OR and sterile processing department, workflow, patient tracking, and instrument management solutions; and cleaning chemistries and sterility assurance products.

Broadfin Capital Llc increased Nuvasive Inc (NUVA) stake by 57.42% reported in 2017Q3 SEC filing. Broadfin Capital Llc acquired 32,100 shares as Nuvasive Inc (NUVA)’s stock declined 4.50%. The Broadfin Capital Llc holds 88,000 shares with $4.88 million value, up from 55,900 last quarter. Nuvasive Inc now has $2.46 billion valuation. The stock increased 0.44% or $0.21 during the last trading session, reaching $48.21. About 705,521 shares traded. NuVasive, Inc. (NASDAQ:NUVA) has risen 33.31% since February 18, 2017 and is uptrending. It has outperformed by 16.61% the S&P500.

The stock increased 0.69% or $0.62 during the last trading session, reaching $90.11. About 268,289 shares traded. Steris Plc (STE) has risen 7.97% since February 18, 2017 and is uptrending. It has underperformed by 8.73% the S&P500.

Fruth Investment Management holds 0.61% of its portfolio in Steris Plc for 15,076 shares. Ghp Investment Advisors Inc. owns 19,585 shares or 0.26% of their US portfolio. Moreover, Gotham Asset Management Llc has 0.07% invested in the company for 55,355 shares. The Vermont-based Hanson & Doremus Investment Management has invested 0.05% in the stock. Shell Asset Management Co, a Netherlands-based fund reported 36,726 shares.

Investors sentiment decreased to 0.95 in 2017 Q3. Its down 0.28, from 1.23 in 2017Q2. It worsened, as 67 investors sold NUVA shares while 69 reduced holdings. 47 funds opened positions while 82 raised stakes. 53.88 million shares or 3.45% less from 55.81 million shares in 2017Q2 were reported. State Treasurer State Of Michigan has 19,100 shares for 0.01% of their portfolio. Strs Ohio reported 0% in NuVasive, Inc. (NASDAQ:NUVA). Citigroup accumulated 20,251 shares. Lenox Wealth invested 0% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA). Fiera has invested 0.02% in NuVasive, Inc. (NASDAQ:NUVA). State Common Retirement Fund reported 133,470 shares. Tower Research Cap Ltd Liability Company (Trc) has 0.04% invested in NuVasive, Inc. (NASDAQ:NUVA) for 7,971 shares. Broadfin Limited Liability Company holds 0.72% or 88,000 shares. Great West Life Assurance Company Can holds 30,628 shares. Fisher Asset Ltd Llc holds 0.1% or 1.31M shares in its portfolio. 117,341 are held by Barclays Public Ltd Company. Morgan Stanley reported 0.01% in NuVasive, Inc. (NASDAQ:NUVA). 13,600 were reported by Louisiana State Employees Retirement Sys. Mason Street Advsr Llc owns 25,216 shares for 0.03% of their portfolio. Credit Suisse Ag accumulated 120,896 shares.

Broadfin Capital Llc decreased Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) stake by 106,992 shares to 74,208 valued at $8.72M in 2017Q3. It also reduced Aerie Pharmaceuticals Inc (Call) (NASDAQ:AERI) stake by 160,000 shares and now owns 150,000 shares. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: